#USA #Boston #Huntington's Disease #Skyhawk Therapeutics #SKY-0515

Skyhawk Therapeutics Releases Interim Results on Clinical Trial

Skyhawk Therapeutics, a biotechnology company focused on developing novel small-molecule therapies, has recently announced the twelve-month interim results of its Phase 1/2 clinical trial evaluating SKY-0515, a potential treatment for Huntington's disease (HD). The findings have sparked hope among patients and medical professionals alike.

Significant Improvements Observed

The twelve-month results revealed a notable improvement on the Composite Unified Huntington's Disease Rating Scale (cUHDRS), with scores increasing by +0.38 compared to the expected decline of -0.92 points based on natural disease progression in symptomatic patients. This change suggests that SKY-0515 may effectively mitigate the symptoms associated with HD.

Most impressively, patients receiving the 9 mg dose of SKY-0515 experienced a significant reduction in the mutated Huntington protein (mHTT) by 69%. The safety profile of the drug appeared robust, with SKY-0515 demonstrating excellent exposure in the central nervous system and being generally well-tolerated across all dosages tested.

The FALCON-HD Study

The company also made headlines by announcing that the recruitment phase for its pivotal FALCON-HD study in Australia and New Zealand had concluded six months ahead of schedule, enrolling 144 patients. Moreover, the global scale of the study has expanded to include eight countries. A total of over 175 patients are now involved in both the Phase 1/2 trial and the FALCON-HD program, pushing forward the quest for groundbreaking treatment options for HD.

Bill Haney, Co-founder and CEO of Skyhawk, expressed confidence in the results, stating, “The increasing divergence of clinical trajectories from the expected natural progression at the twelve-month mark signals promising sustained benefits for Huntington's patients.” The combination of reduced critical biomarkers mHTT and PMS1, along with positive clinical outcomes across various cUHDRS components, has strengthened the belief in the unique mechanism of action of SKY-0515.

Expert Insights

Dr. Phillip Sharp, a founding member of Skyhawk's scientific advisory board and Nobel laureate, emphasized the significance of these results, stating, “skyhawk demonstrates the remarkable ability to modulate RNA splicing with a small molecule, providing a much-needed therapeutic avenue for patients globally.” This core innovation in RNA modulation paves the way for potential treatments embraced by the medical community.

Ed Wild, a neurology professor at University College London, described the results as “encouraging,” highlighting the drug's capacity to sustain a reduction in mHTT protein while being well-tolerated. He described the combined action of SKY-0515 on both mHTT and PMS1 proteins as a potent approach targeting two critical mechanisms at the heart of Huntington's pathology.

The Future of Huntington's Disease Treatment

The hope for Huntington's disease sufferers lies in developing SKY-0515 as a daily oral treatment. Sergey Pauskin, Co-founder and Head of Research and Development at Skyhawk, pointed out that the proprietary SKYSTAR® platform enables the development of transformative medications that patients can take at home. With the positive results from this Phase-1/2 study, Skyhawk is set to evaluate further therapies targeting various neurological disorders that currently lack approved treatments.

As the company moves toward the next development phase of SKY-0515, they remain committed to making groundbreaking therapies available to the Huntington's community as soon as possible. The potential of this treatment to alter the course of Huntington's disease cannot be understated, offering hope to those affected by this debilitating condition.

In the fight against Huntington's disease, innovative research like that seen in the skyhawk program serves as a ray of hope, transforming patient expectations into a reality where effective management of symptoms can significantly improve the quality of life for thousands.